Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 4/20 | 0.53 |
| ▸ | RAF1 | P04049 | 3/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.52 |
| ▸ | CCNC | P24863 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 11/20 | 0.48 |
| ▸ | BRAF | P15056 | 7/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25420133 | 1.00 | CDK8 (0.53) | CDK8RAF1MAPK3CCNCKDR | |
| SCHEMBL26074904 | 0.91 | CDK8 (0.61) | CDK8RAF1MAPK3CCNCKDR | |
| SCHEMBL26075423 | 0.89 | RAF1 (0.48) | CDK8RAF1MAPK3CCNCKDR | |
| SCHEMBL26075420 | 0.88 | RAF1 (0.47) | CDK8RAF1MAPK3CCNCKDR | |
| SCHEMBL25421713 | 0.86 | MET (0.37) | RAF1MAPK3KDRBRAFMET | |
| SCHEMBL29537267 | 0.85 | MET (0.37) | CDK8RAF1MAPK3KDRRET | |
| SCHEMBL29536773 | 0.84 | EPHX2 (0.44) | CDK8CCNCMET | |
| SCHEMBL26074902 | 0.84 | EPHX2 (0.44) | CDK8CCNCMET | |
| SCHEMBL26074956 | 0.81 | MET (0.51) | KDRRETMET | |
| SCHEMBL26075414 | 0.81 | AXL (0.37) | CDK8RAF1CCNCKDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | CDK8 228/4885RAF1 115/4885MAPK3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.